T1	Participants 112 158	patients with untreated acute myeloid leukemia
T2	Participants 500 555	idarubicin and daunorubicin that began in 1984 and 1985
T3	Participants 582 637	Memorial Sloan-Kettering Cancer Center (MSKCC), the U.S
T4	Participants 672 708	Southeastern Cancer Study Group (SEG
